Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Revenue of Summit Therapeutics Inc. (SMMT)
Revenue in 2023 (TTM): $
According to Summit Therapeutics Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Summit Therapeutics Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-2,050,000 | $1 M | $-615,874,000 | $-614,928,000 |
| 2022 | $704.3 K | $-1,809,705 | $-52,630,218 | $-78,782,000 | $-74,381,000 |
| 2021 | $1.81 M | $1.81 M | $-62,735,895 | $-88,602,000 | $-86,147,000 |
| 2020 | $860 K | $860 K | $-37,134,337 | $-52,910,000 | $-52,697,000 |
| 2019 | $632.02 K | $476.62 K | $-16,795,207 | $-28,408,302 | $-23,884,438 |
| 2018 | $56.41 M | $56.39 M | $11.66 M | $6.6 M | $9.87 M |
| 2017 | $35.98 M | $35.88 M | $-32,191,994 | $-15,418,696 | $-10,093,704 |
| 2016 | $2.88 M | $2.88 M | $-30,982,588 | $-32,132,545 | $-26,712,748 |
| 2015 | $ | $ | $-20,298,000 | $-28,691,875 | $-24,336,680 |
| 2014 | $2.27 M | $2.27 M | $-12,200,000 | $-19,074,883 | $-17,120,687 |
| 2013 | $2.27 M | $2.27 M | $-11,023,687 | $-11,051,729 | $-10,050,475 |
| 2012 | $2.87 M | $2.87 M | $-5,482,460 | $-7,212,017 | $-6,673,406 |
| 2011 | $2.77 M | $1.77 M | $-4,407,839 | $-4,707,767 | $-4,230,395 |
| 2010 | $1.21 M | $1.21 M | $-8,645,218 | $-9,362,093 | $-7,421,943 |
| 2009 | $301.95 K | $301.95 K | $-5,406,269 | $-9,296,418 | $-8,657,379 |
| 2008 | $266.64 K | $260.87 K | $-16,025,770 | $-18,880,978 | $-32,289,355 |
| 2007 | $6.03 M | $3.51 M | $-18,582,593 | $-21,939,191 | $-20,127,662 |
| 2006 | $2.03 M | $1.43 M | $-6,133,658 | $-6,882,956 | $-5,923,776 |
| 2005 | $947.89 K | $531.96 K | $-2,972,206 | $-2,171,763 | $-1,893,286 |
| 2004 | $212.76 K | $43.31 K | $-527,198 | $-131,799 | $-86,611 |
| 2003 | $1.82 K | $ | $-41,963 | $-41,963 | $-41,963 |